Apabetalone/RVX-208 (1),the first reported BET BD2 biased compound, demonstrates a 10-foldselectivity over BET BD1.19 This moleculehas advanced into multiple clinical trials for major adverse cardiacevents and, more recently, for Covid-19 treatment.20 With a much improved 330-fold selectivity over BET BD1,ABBV-744 (2) became the first highly selective BET BD2molecule to progress into clinical trials, although the phase I studyin acute myeloid leukemia was terminated for strategic reasons.21,22. The gene discussed is DNER; the disease is acute myeloid leukemia.